DAUPHIN COUNTY, Pa. (WHTM) – Loyal, a biotech company pioneering longevity drugs for dogs, announced that it has dosed the first dog in its STAY study, the pivotal clinical trial for its LOY-002 drug.
LOY-002 is being developed by Loyal to extend the healthy lifespan of senior dogs and maintain their quality of life as they age.
The study is designed to provide pivotal effectiveness and field safety data in support of
the company’s application for approval with the Food and Drug Administration.
“ Were developing this drug to help extend the life of span of senior dogs and maintain their quality of life as they age, ” said John Purcell, the Executive Creative Director for Loyal.
Purcell added, “Rather than the typical way we think of medication, curing disease. This is really about addressing a whole set of age associated diseases.”
Loyal is pursuing conditional approval for the drug, which would allow it to begin offering
LOY-002 through veterinarians as soon as early 2025.
A dog right here in the Midstate is a participant! 11-year-old Boo, owned by Deb Hanna, has been on the medication for about a month.